EE04966B1 - (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks - Google Patents

(-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks

Info

Publication number
EE04966B1
EE04966B1 EEP200200695A EEP200200695A EE04966B1 EE 04966 B1 EE04966 B1 EE 04966B1 EE P200200695 A EEP200200695 A EE P200200695A EE P200200695 A EEP200200695 A EE P200200695A EE 04966 B1 EE04966 B1 EE 04966B1
Authority
EE
Estonia
Prior art keywords
chlorophenyl
alpha
preparation
tetrazolo
methanamine
Prior art date
Application number
EEP200200695A
Other languages
English (en)
Estonian (et)
Inventor
Gaston Venet Marc
Ren� Angibaud Patrick
William End David
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200200695A publication Critical patent/EE200200695A/xx
Publication of EE04966B1 publication Critical patent/EE04966B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200695A 2000-06-22 2001-06-13 (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks EE04966B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (fr) 2000-06-22 2001-06-13 Farnesyl transferase inhibant un enantiomere de quinoline 1,2 cyclise

Publications (2)

Publication Number Publication Date
EE200200695A EE200200695A (et) 2004-06-15
EE04966B1 true EE04966B1 (et) 2008-02-15

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200695A EE04966B1 (et) 2000-06-22 2001-06-13 (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks

Country Status (34)

Country Link
US (3) US20030114471A1 (fr)
EP (1) EP1296984B1 (fr)
JP (1) JP4919575B2 (fr)
KR (2) KR100831940B1 (fr)
CN (1) CN1207296C (fr)
AR (1) AR030704A1 (fr)
AT (1) ATE294804T1 (fr)
AU (3) AU6396201A (fr)
BG (1) BG65894B1 (fr)
BR (1) BRPI0111743B8 (fr)
CA (1) CA2410232C (fr)
CZ (1) CZ295278B6 (fr)
DE (1) DE60110592T2 (fr)
EA (1) EA005065B1 (fr)
EE (1) EE04966B1 (fr)
EG (1) EG24180A (fr)
ES (1) ES2241830T3 (fr)
HK (1) HK1058363A1 (fr)
HR (1) HRP20020989B1 (fr)
HU (1) HU229095B1 (fr)
IL (2) IL153560A0 (fr)
IS (1) IS2596B (fr)
JO (1) JO2361B1 (fr)
MX (1) MXPA02012845A (fr)
MY (1) MY127734A (fr)
NO (1) NO324494B1 (fr)
NZ (1) NZ522481A (fr)
PA (1) PA8519501A1 (fr)
PL (1) PL209521B1 (fr)
SA (1) SA01220349B1 (fr)
SK (1) SK285699B6 (fr)
UA (1) UA73572C2 (fr)
WO (1) WO2001098302A1 (fr)
ZA (1) ZA200210305B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (fr) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Procede d'utilisation de 5-(arylsulfonyle)-,5-(arylsulfinyle), et 5-(arylsulfanyle)-thiazolidine-2,4-diones pour l'inhibition de la farnesyle-proteine transferase
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (fr) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Traitement d'une infection au virus de l'hépatite delta
DK3285768T3 (da) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
DK3640345T3 (da) 2015-08-17 2022-01-03 Kura Oncology Inc Fremgangsmåder til at behandle kræftpatienter med farnesyltransferaseinhibitorer
PL3534885T3 (pl) 2016-11-03 2021-11-15 Kura Oncology, Inc. Inhibitory farnezylotransferazy do zastosowania w leczeniu nowotworu

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
AU711142B2 (en) * 1995-12-08 1999-10-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-YL)methyl-2-quinolinone derivatives
EP0891334A1 (fr) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PL190944B1 (pl) * 1997-04-25 2006-02-28 Janssen Pharmaceutica Nv Pochodna chinazolinonu i sposób jej wytwarzania oraz kompozycja farmaceutyczna i sposób jej wytwarzania
TR199902923T2 (xx) 1997-06-02 2000-11-21 Janssen Pharmaceutica N.V. Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
PL193464B1 (pl) * 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
SK285231B6 (sk) 1998-07-06 2006-09-07 Janssen Pharmaceutica N. V. Použitie 6-[(imidazol-5-yl)metyl]chinolínovej zlúčeniny na prípravu farmaceutickej kompozície na liečbu artropatie
SK2442001A3 (en) * 1998-08-27 2002-10-08 Pfizer Prod Inc Alkynyl-substituted quinolin-2-ones, pharmaceutical compositions, their use in the treatment and method for producing thereof
CA2341739C (fr) * 1998-08-27 2005-07-12 Pfizer Products Inc. Derives de quinolin-2-one utiles en tant qu'agents anticancereux
EA004542B1 (ru) * 1998-12-23 2004-06-24 Янссен Фармацевтика Н.В. 1, 2-аннелированные производные хинолина
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
KR20010102073A (ko) * 1999-02-11 2001-11-15 실버스타인 아써 에이. 항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
AU2002220559A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
EA005065B1 (ru) 2004-10-28
JP4919575B2 (ja) 2012-04-18
PA8519501A1 (es) 2002-08-29
CA2410232A1 (fr) 2001-12-27
US20030114471A1 (en) 2003-06-19
MXPA02012845A (es) 2003-05-15
EP1296984B1 (fr) 2005-05-04
SK502003A3 (en) 2003-05-02
HRP20020989A2 (en) 2005-02-28
IS6590A (is) 2002-10-25
ES2241830T3 (es) 2005-11-01
EA200300048A1 (ru) 2003-04-24
NO20026032L (no) 2002-12-16
IL153560A (en) 2011-06-30
DE60110592D1 (de) 2005-06-09
CZ2003114A3 (cs) 2003-05-14
CZ295278B6 (cs) 2005-06-15
HUP0300872A2 (hu) 2003-07-28
BR0111743A (pt) 2003-07-08
MY127734A (en) 2006-12-29
HK1058363A1 (en) 2004-05-14
HU229095B1 (en) 2013-07-29
IL153560A0 (en) 2003-07-06
CA2410232C (fr) 2008-10-07
SK285699B6 (sk) 2007-06-07
KR100831940B1 (ko) 2008-05-23
WO2001098302A1 (fr) 2001-12-27
CN1207296C (zh) 2005-06-22
PL209521B1 (pl) 2011-09-30
JP2004501153A (ja) 2004-01-15
SA01220349B1 (ar) 2007-01-23
NZ522481A (en) 2004-09-24
NO324494B1 (no) 2007-10-29
EE200200695A (et) 2004-06-15
US8318753B2 (en) 2012-11-27
KR100846370B1 (ko) 2008-07-15
AU2001263962B2 (en) 2006-07-20
US20070259902A1 (en) 2007-11-08
DE60110592T2 (de) 2006-01-19
US8329714B2 (en) 2012-12-11
NO20026032D0 (no) 2002-12-16
ZA200210305B (en) 2004-03-19
AR030704A1 (es) 2003-09-03
ATE294804T1 (de) 2005-05-15
CN1437601A (zh) 2003-08-20
PL358918A1 (en) 2004-08-23
AU2006220405B2 (en) 2009-05-21
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
AU6396201A (en) 2002-01-02
JO2361B1 (en) 2006-12-12
KR20070121847A (ko) 2007-12-27
HUP0300872A3 (en) 2004-11-29
BG107310A (bg) 2003-07-31
BRPI0111743B8 (pt) 2021-05-25
AU2006220405A1 (en) 2006-10-12
EG24180A (en) 2008-09-28
KR20030009463A (ko) 2003-01-29
US20080114009A1 (en) 2008-05-15
HRP20020989B1 (en) 2011-05-31
BG65894B1 (bg) 2010-04-30
UA73572C2 (en) 2005-08-15
EP1296984A1 (fr) 2003-04-02

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
JP2005537234A5 (fr)
AR048324A1 (es) Metodos para tratar infecciones por vih
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
CA2416492A1 (fr) Traitement de la glycogenose de type ii
WO2002040702A3 (fr) Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
EE04966B1 (et) (-)-5-(3-klorofenl)-alfa-(4-klorofenl)-alfa-(1-metl-1H-imidasool-5-l)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
WO2002102743A3 (fr) Aminoalkylesters d'acide diphenylalcoxy-acetique n et alpha-substitues deuterises et medicaments contenant lesdits composes
MXPA05012826A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen.
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására
JO2296B1 (en) Substituted pyrolates
ATE308995T1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen
WO2003066806A3 (fr) Utilisation therapeutique de composes aziridino
JO2360B1 (en) Substituted pyrolates

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231